Our strength is fuelled by early identification of molecules, building robust API processes, and targeting early launch opportunities in key markets through complete backward integration. Our first API manufacturing facility was established in 2007 to develop high-quality, cost-effective products as import substitutes through indigenous R&D. Our API manufacturing facilities are spread across four different locations and are accredited by stringent global regulatory authorities. The APIs manufactured by us are considered to be of global standards and are being used to manufacture finished products to supply highly regulated markets. We also have a world-class oncology formulation facility that operates under global regulatory and safety standards. Our Ahmedabad SEZ caters exclusively to the US, Europe and other regulated markets.
As a part of the progressive future strategy, we have invested in Pharmez 2 – a highly advanced expansion of our Pharmez SEZ facility in Gujarat, India. This new age, highly automated and efficient manufacturing layout can produce more than one billion solid orals per month as well as 5 million injectable units. This futuristic Pharmez 2 facility is set to be the cornerstone of our promising future.